Belimumab (10 mg / kg IV every 2 weeks for 3 doses, then 10 mg / kg IV once a month or 200 mg subcutaneously once a week) should be considered if patients have uncontrolled disease or frequent flares, particularly for joint, skin, or nonsevere hematologic manifestations (2).